Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVIS-ion trial of low-dose aspirin for cognitive decline in healthy older adults
ACTRN12609000613202Phase 4Active, not recruiting
- Sponsor
- Australian National University
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity comparing Aspirin with Placebo (2 arms). Primary endpoints: Change in brain MRI markers and Change in retinal vascular imaging parameters. Started Apr 2010; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on ACTRN12609000613202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000613202.